Get Premium to unlock powerful stock data

Cormorant Asset Management, LP Buys Beam Therapeutics Inc, Ventyx Biosciences Inc, Verve Therapeutics Inc, Sells Atea Pharmaceuticals Inc, Agenus Inc, Olema Pharmaceuticals inc

Author's Avatar
Feb 18, 2022
Article's Main Image
Investment company Cormorant Asset Management, LP (Current Portfolio) buys Beam Therapeutics Inc, Ventyx Biosciences Inc, Verve Therapeutics Inc, ChemoCentryx Inc, Adicet Bio Inc, sells Atea Pharmaceuticals Inc, Agenus Inc, Olema Pharmaceuticals inc, Revolution Medicines Inc, Ascendis Pharma A/S during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Cormorant Asset Management, LP. As of 2021Q4, Cormorant Asset Management, LP owns 78 stocks with a total value of $1.7 billion. These are the details of the buys and sells.

For the details of Cormorant Asset Management, LP's stock buys and sells, go to https://www.gurufocus.com/guru/cormorant+asset+management%2C+lp/current-portfolio/portfolio

These are the top 5 holdings of Cormorant Asset Management, LP
  1. Erasca Inc (ERAS) - 10,505,550 shares, 9.74% of the total portfolio.
  2. Turning Point Therapeutics Inc (TPTX) - 3,025,000 shares, 8.58% of the total portfolio. Shares added by 6.43%
  3. Design Therapeutics Inc (DSGN) - 5,440,453 shares, 6.93% of the total portfolio. Shares added by 1.41%
  4. Prometheus Biosciences Inc (RXDX) - 1,848,024 shares, 4.35% of the total portfolio.
  5. Prometheus Biosciences Inc (RXDX) - 1,848,024 shares, 4.35% of the total portfolio.
New Purchase: Ventyx Biosciences Inc (VTYX)

Cormorant Asset Management, LP initiated holding in Ventyx Biosciences Inc. The purchase prices were between $14.2 and $23.07, with an estimated average price of $18.94. The stock is now traded at around $10.300000. The impact to a portfolio due to this purchase was 0.9%. The holding were 785,303 shares as of 2021-12-31.

New Purchase: ChemoCentryx Inc (CCXI)

Cormorant Asset Management, LP initiated holding in ChemoCentryx Inc. The purchase prices were between $18.51 and $40.5, with an estimated average price of $35.46. The stock is now traded at around $30.400000. The impact to a portfolio due to this purchase was 0.87%. The holding were 400,000 shares as of 2021-12-31.

New Purchase: Adicet Bio Inc (ACET)

Cormorant Asset Management, LP initiated holding in Adicet Bio Inc. The purchase prices were between $7.37 and $17.49, with an estimated average price of $10.83. The stock is now traded at around $14.660000. The impact to a portfolio due to this purchase was 0.78%. The holding were 750,000 shares as of 2021-12-31.

New Purchase: Keros Therapeutics Inc (KROS)

Cormorant Asset Management, LP initiated holding in Keros Therapeutics Inc. The purchase prices were between $36.95 and $62.89, with an estimated average price of $50.29. The stock is now traded at around $52.060000. The impact to a portfolio due to this purchase was 0.52%. The holding were 150,000 shares as of 2021-12-31.

New Purchase: Pyxis Oncology Inc (PYXS)

Cormorant Asset Management, LP initiated holding in Pyxis Oncology Inc. The purchase prices were between $8.39 and $13.64, with an estimated average price of $11.44. The stock is now traded at around $7.390000. The impact to a portfolio due to this purchase was 0.42%. The holding were 668,854 shares as of 2021-12-31.

New Purchase: Celldex Therapeutics Inc (CLDX)

Cormorant Asset Management, LP initiated holding in Celldex Therapeutics Inc. The purchase prices were between $35.68 and $56.27, with an estimated average price of $43.33. The stock is now traded at around $30.250000. The impact to a portfolio due to this purchase was 0.23%. The holding were 100,000 shares as of 2021-12-31.

Added: Beam Therapeutics Inc (BEAM)

Cormorant Asset Management, LP added to a holding in Beam Therapeutics Inc by 400.00%. The purchase prices were between $68.02 and $99.06, with an estimated average price of $85.57. The stock is now traded at around $69.020000. The impact to a portfolio due to this purchase was 1.9%. The holding were 500,000 shares as of 2021-12-31.

Added: Verve Therapeutics Inc (VERV)

Cormorant Asset Management, LP added to a holding in Verve Therapeutics Inc by 56.40%. The purchase prices were between $31.94 and $54.82, with an estimated average price of $41.79. The stock is now traded at around $28.020000. The impact to a portfolio due to this purchase was 0.88%. The holding were 1,109,224 shares as of 2021-12-31.

Added: Tango Therapeutics Inc (TNGX)

Cormorant Asset Management, LP added to a holding in Tango Therapeutics Inc by 25.65%. The purchase prices were between $9.55 and $14.29, with an estimated average price of $11.97. The stock is now traded at around $8.950000. The impact to a portfolio due to this purchase was 0.65%. The holding were 4,899,185 shares as of 2021-12-31.

Added: Centessa Pharmaceuticals PLC (CNTA)

Cormorant Asset Management, LP added to a holding in Centessa Pharmaceuticals PLC by 44.15%. The purchase prices were between $10.99 and $17.54, with an estimated average price of $13.36. The stock is now traded at around $9.580000. The impact to a portfolio due to this purchase was 0.51%. The holding were 2,489,894 shares as of 2021-12-31.

Added: IGM Biosciences Inc (IGMS)

Cormorant Asset Management, LP added to a holding in IGM Biosciences Inc by 42.86%. The purchase prices were between $27.59 and $66.39, with an estimated average price of $49.24. The stock is now traded at around $16.250000. The impact to a portfolio due to this purchase was 0.26%. The holding were 500,000 shares as of 2021-12-31.

Sold Out: Agenus Inc (AGEN)

Cormorant Asset Management, LP sold out a holding in Agenus Inc. The sale prices were between $2.92 and $5.74, with an estimated average price of $3.98.

Sold Out: Blueprint Medicines Corp (BPMC)

Cormorant Asset Management, LP sold out a holding in Blueprint Medicines Corp. The sale prices were between $94.25 and $115.99, with an estimated average price of $104.74.

Sold Out: I-MAB (IMAB)

Cormorant Asset Management, LP sold out a holding in I-MAB. The sale prices were between $45.28 and $74.5, with an estimated average price of $59.71.

Sold Out: Omeros Corp (OMER)

Cormorant Asset Management, LP sold out a holding in Omeros Corp. The sale prices were between $5.67 and $8.29, with an estimated average price of $7.25.

Sold Out: Inspire Medical Systems Inc (INSP)

Cormorant Asset Management, LP sold out a holding in Inspire Medical Systems Inc. The sale prices were between $207.57 and $280.17, with an estimated average price of $244.16.

Sold Out: Reata Pharmaceuticals Inc (RETA)

Cormorant Asset Management, LP sold out a holding in Reata Pharmaceuticals Inc. The sale prices were between $25.61 and $110.96, with an estimated average price of $75.97.



Here is the complete portfolio of Cormorant Asset Management, LP. Also check out:

1. Cormorant Asset Management, LP's Undervalued Stocks
2. Cormorant Asset Management, LP's Top Growth Companies, and
3. Cormorant Asset Management, LP's High Yield stocks
4. Stocks that Cormorant Asset Management, LP keeps buying
Rating:
0 / 5 (0 votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles